hMSC-Derived VEGF Release Triggers the Chemo-Attraction of Alveolar Osteoblasts
Scientists showed by live cell imaging that in interactive cocultures, human mesenchymal stem cells (hMSCs) successfully trigger osteoblast chemotaxis. They showed that only corresponding levels of vascular endothelial growth factor (VEGF) but not osteoprotegerin attracted alveolar osteoblasts similar to hMSC coculture, while VEGF inhibitor abolished both the VEGF and the hMSC-triggered chemo-attraction. [Stem Cells] Abstract
Mesenchymal Stem Cell Expression of SDF-1β Synergizes with BMP-2 to Augment Cell-Mediated Healing of Critical-Sized Mouse Calvarial Defects
The authors tested the hypothesis that stromal cell-derived factor-1β (SDF-1β) overexpressed in Tet-Off-SDF-1β bone marrow-derived mesenchymal stem/stromal cells (BMSCs), delivered on acellular dermal matrix, synergistically augments bone morphogenetic protein-2 (BMP-2)-induced healing of critical-sized mouse calvarial defects. BMSC therapies alone showed limited bone healing, which was increased with co-delivery of BMP-2. [J Tissue Eng Regen Med] Abstract
Effects of Tanshinone IIA on Osteogenic Differentiation of Mouse Bone Marrow Mesenchymal Stem Cells
Both ALP activity at day 7 and calcium content at day 24 were upregulated during the osteogenesis of mouse bone marrow mesenchymal stem cells treated with tanshinone IIA (TSA), demonstrating that it promoted the osteogenesis at both early and late stages. They found that TSA promoted osteogenesis and inhibited osteoclastogenesis, evident by RT-PCR analysis of osteogenic marker gene expressions. [Naunyn Schmiedebergs Arch Pharmacol] Abstract
Mesenchymal Stem Cells in Autism Spectrum and Neurodevelopmental Disorders: Pitfalls and Potential Promises
The relevant literature in autism spectrum disorders and other neurodevelopmental disorders regarding immune dysregulation and neuroinflammation and relevant therapeutics with mesenchymal stem cell infusion is reviewed. The relevant literature pertaining to mesenchymal stem cells and their clinical applications is also reviewed. [World J Biol Psychiatry] Abstract
Visit our reviews page to see a complete list of reviews in the mesenchymal cell research field.
INDUSTRY NEWS
The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor
AmnioChor Inc. announced that the Musculoskeletal Transplant Foundation of Edison NJ has agreed to invest in their seed round of development of the proprietary AmnioCept™ product line and OmniBank placental tissue storage capabilities. AmnioChor’s products are intended to augment umbilical cord blood, and will additionally contain epithelial and mesenchymal stem cells that may be used in technologies including 3-D printing of human organs. [AmnioChor Inc. (PR Newswire Association LLC)]
Press Release
Cynata Collaborates with University of Sydney to Evaluate Cymerus™ MSCs for Heart Disease
Cynata Therapeutics Ltd announced that it has initiated a collaboration with the University of Sydney to test the potential therapeutic efficacy of its Cymerus™ mesenchymal stem cells (MSCs) in animal models of myocardial infarction (heart attack) and associated heart rhythm abnormalities. [Cynata Therapeutics Ltd] Press Release
Recruit Top Talent:
Reach more than 60,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!
